Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001613
Other study ID # 970121
Secondary ID 97-EI-0121
Status Completed
Phase N/A
First received November 3, 1999
Last updated March 3, 2008
Start date May 1997
Est. completion date May 2002

Study information

Verified date May 2002
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

Cataract, in which the lens of the eye is opacified, is the major cause of blindness. This study will examine protein material of the lens called crystallins to try to determine what causes nuclear cataracts, a type of cataract that forms in the central lens nucleus.

Men and women age 45 years or older with a cataract may be eligible for this study. Candidates will be screened to determine what type of cataract they have and will undergo a complete eye examination, including a vision test, eye pressure test, and examination of the lens and retina.

Patients selected for study will have a complete physical and eye examination, including photography of various parts of the eye, and ultrasound measurements of the eye. They will then have cataract surgery, either with or without intraocular lens implantation, and will have follow-up examinations 1 week, 3 weeks, 5 weeks and 8 weeks after surgery.

Tissue from the lenses removed during surgery will be given to NEI scientists for research on the causes of age-related nuclear cataracts.


Description:

Progress has been made in elucidating causative factors for some cataracts but little is yet known about those factors involved in development of aging-related nuclear cataracts. The predominant theory of nuclear cataractogenesis is that the lens crystallins accumulate covalent modifications which ultimately lead to increased light scattering. This theory is based on several lines of evidence. Crystallins, the predominant components of the lens, are present at very high concentration and determine the refractive properties of the lens. A relationship between crystallin alterations and cataract formation comes from studies on animal cataract models where mutations in crystallin genes have been identified. Numerous studies have also demonstrated that covalent modification of crystallins occurs in the human lens. These modifications are reported to be developmentally related, age related and/or the result of toxic environmental influences. Data from this lab demonstrated that the human lens crystallins undergo extensive covalent modification as part of normal lens fiber cell maturation. Crystallin modifications that cause cataracts would have to be superimposed on these normally occurring modifications.

We have begun a study under the protocol entitled "Use of Human Lens Material for Possible Causes of Cataract" to compare crystallins in nuclear cataracts with those in normal lenses. The goal was to identify uniquely altered crystallins, isolate the modified species and determine the covalent modifications that could possibly be involved in cataract formation. Surprisingly, our preliminary findings indicated that the pattern of protein spots on a 2-dimensional display of the total lens proteins (soluble, water insoluble and membrane) in the nuclear region of nuclear cataracts is essentially the same as found in the nucleus of normal lenses. Only the relative concentrations of these protein species varied. The number of pure nuclear cataracts available was too few 1) to determine the relationship between nuclear cataracts and crystallin covalent modification and 2) to establish the significance of concentration differences in crystallin species between normal lenses and nuclear cataracts. Therefore, the purpose of this protocol is to recruit enough subjects with pure nuclear cataracts to complete this study which should provide significant insights into the mechanisms underlying nuclear cataract.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date May 2002
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility INCLUSION CRITERIA:

Patients with cataracts will be screened in order to determine eligibility.

Patients 45 years and older of either sex with clinically significant cataract will be admitted to this study.

Patients requiring cataract surgery should have either age related nuclear cataracts or cortical and/or posterior subcapsular cataract without nuclear cataract (controls).

Age related nuclear cataract is defined using LOCS II Clinical Classification as having Nuclear color of 0-2, Nuclear Opalescence of 2-5, Cortical Opacity 0-1, and PSC 0-1.

In addition, for controls, patients of either sex with clinically significant cortical or posterior subcapsular cataracts but having no nuclear cataract will also be recruited. These will have a LOCS grade of Nuclear Color 0-2, Nuclear Opalescence 0-1, Cortical 1-5, PSC 1.4.

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Eye Institute (NEI) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Datiles MB, Schumer DJ, Zigler JS Jr, Russell P, Anderson L, Garland D. Two-dimensional gel electrophoretic analysis of human lens proteins. Curr Eye Res. 1992 Jul;11(7):669-77. — View Citation

Dilley KJ. The proportion of protein from the normal and cataractous human lens which exists as high molecular weight aggregates in vitro. Exp Eye Res. 1975 Jan;20(1):73-8. — View Citation

Foster A, Johnson GJ. Magnitude and causes of blindness in the developing world. Int Ophthalmol. 1990 May;14(3):135-40. Review. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A